TYRA Latest Press Releases

-- October 15, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA PRNewswire 10:01 AM

-- October 13, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA Globe Newswire 5:48 PM

-- October 1, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA PRNewswire 10:02 AM

-- September 29, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA Globe Newswire 5:33 PM

-- September 15, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA Globe Newswire 5:32 PM

-- September 14, 2026 --

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants PRNewswire 6:45 AM

-- September 10, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA PRNewswire 7:20 PM

-- September 9, 2026 --

Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib PRNewswire 7:00 AM

-- September 8, 2026 --

Tyra Biosciences to Present at the Cantor Global Healthcare Conference PRNewswire 4:05 PM

-- September 4, 2026 --

Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 PRNewswire 8:01 AM

-- August 4, 2026 --

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights PRNewswire 4:05 PM

Market Data Delayed 15 Minutes